SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Frangoul H.)
 

Sökning: WFRF:(Frangoul H.) > (2015-2019) > GvHD after umbilica...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007810naa a2200865 4500
001oai:DiVA.org:uu-320834
003SwePub
008170426s2017 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:135472726
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3208342 URI
0247 a https://doi.org/10.1038/bmt.2016.2652 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1354727262 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Chen, Y-Bu Massachusetts Gen Hosp, Yawkey 9E 9052 55 Fruit St, Boston, MA 02114 USA.4 aut
2451 0a GvHD after umbilical cord blood transplantation for acute leukemia :b an analysis of risk factors and effect on outcomes
264 c 2016-12-12
264 1b NATURE PUBLISHING GROUP,c 2017
338 a print2 rdacarrier
520 a Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we analyzed 1404 umbilical cord blood transplantation (UCBT) patients (single (>= 18 years) = 810, double (< 18 years) = 594) with acute leukemia to define the incidence of acute GvHD (aGvHD) and chronic GvHD (cGvHD), analyze clinical risk factors and investigate outcomes. After single UCBT, 100-day incidence of grade II-IV aGvHD was 39% (95% confidence interval (CI), 36-43%), grade III-IV aGvHD was 18% (95% CI, 15-20%) and 1-year cGvHD was 27% (95% CI, 24-30%). After double UCBT, 100-day incidence of grade II-IV aGvHD was 45% (95% CI, 41-49%), grade III-IV aGvHD was 22% (95% CI, 19-26%) and 1-year cGvHD was 26% (95% CI, 22-29%). For single UCBT, multivariate analysis showed that absence of antithymocyte globulin (ATG) was associated with aGvHD, whereas prior aGvHD was associated with cGvHD. For double UCBT, absence of ATG and myeloablative conditioning were associated with aGvHD, whereas prior aGvHD predicted for cGvHD. Grade III-IV aGvHD led to worse survival, whereas cGvHD had no significant effect on disease-free or overall survival. GvHD is prevalent after UCBT with severe aGvHD leading to higher mortality. Future research in UCBT should prioritize prevention of GvHD.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
7001 a Wang, T.u Med Coll Wisconsin, Ctr Int Blood, Marrow Transplant Res, Dept Med, Milwaukee, WI USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI USA.4 aut
7001 a Hemmer, M. T.u Med Coll Wisconsin, Ctr Int Blood, Marrow Transplant Res, Dept Med, Milwaukee, WI USA.4 aut
7001 a Brady, C.u Natl Marrow Donor Program Be Match, Ctr Int Blood, Marrow Transplant Res, Minneapolis, MN USA.4 aut
7001 a Couriel, D. R.u Marrow Transplant Program, Utah Blood, Salt Lake City, UT USA.4 aut
7001 a Alousi, A.u Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Stem Cell Transplantat, Houston, TX 77030 USA.4 aut
7001 a Pidala, J.u H Lee Moffitt Canc Ctr & Res Inst, Res Inst, Tampa, FL USA.4 aut
7001 a Urbano-Ispizua, A.u Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain.;Univ Barcelona, Inst Res Josep Carreras, Dept Hematol, Hosp Clin, Barcelona, Spain.4 aut
7001 a Choi, S. W.u Univ Michigan, Ann Arbor, MI 48109 USA.4 aut
7001 a Nishihori, T.u H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.4 aut
7001 a Teshima, T.u Univ Hosp, Fukuoka, Japan.4 aut
7001 a Inamoto, Y.u Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan.4 aut
7001 a Wirk, B.u Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA.4 aut
7001 a Marks, D. I.u Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England.4 aut
7001 a Abdel-Azim, H.u Univ So Calif, Keck Sch Med, Marrow Transplantat, Div Hematol Oncol & Blood, Los Angeles, CA 90033 USA.4 aut
7001 a Lehmann, L.u Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.4 aut
7001 a Yu, L.u Louisiana State Univ, Med Ctr, Div Hematol Oncol, Childrens Hosp,Ctr Canc & Blood Disorders,HSC, New Orleans, LA USA.4 aut
7001 a Bitan, M.u Tel Aviv Sourasky Med Ctr, Tel Aviv, Dept Pediat Hematol Oncol, Tel Aviv, Israel.4 aut
7001 a Cairo, M. S.u New York Med Coll, Div Pediat Hematol Oncol, Stem Cell Transplantat, Dept Pediat, Valhalla, NY USA.4 aut
7001 a Qayed, M.u Emory Univ, Sch Med, Dept Pediat, Atlanta, GA, Australia.4 aut
7001 a Salit, R.u Fred Hutchinson Canc Res Ctr, Seattle, WA USA.4 aut
7001 a Gale, R. P.u Imperial Coll London, Hematol Res Ctr, Div Expt Med, Dept Med, London, England.4 aut
7001 a Martino, R.u Hosp Santa Creu St Pau, Div Clin Hematol, Barcelona, Spain.4 aut
7001 a Jaglowski, S.u Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA.4 aut
7001 a Bajel, A.u Royal Melbourne Hosp City Campus, Melbourne, Australia.4 aut
7001 a Savani, B.u Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Dept Med, Nashville, TN USA.4 aut
7001 a Frangoul, H.u Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Pediat, Nashville, TN USA.4 aut
7001 a Lewis, I. D.u Royal Adelaide Hosp, Haematol & Bone Marrow Transplant Unit, Adelaide, SA, Australia.4 aut
7001 a Storek, J.u Univ Calgary, Dept Med, Calgary, AB, Canada.4 aut
7001 a Askar, M.u Baylor Univ, Med Ctr, Dallas, TX USA.4 aut
7001 a Kharfan-Dabaja, M. A.u H Lee Mofitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA.4 aut
7001 a Aljurf, M.u King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.4 aut
7001 a Ringden, O.u Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.4 aut
7001 a Reshef, R.u Columbia Univ, Med Ctr, Blood & Marrow Transplantat Program, Columbia Ctr Translat Immunol, New York, NY USA.4 aut
7001 a Olsson, R. F.u Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.4 aut
7001 a Hashmi, S.u Mayo Clin Rochester, Rochester, MN USA.4 aut
7001 a Seo, S.u Nat Canc Res Ctr, East Hosp, Kashiwa, Chiba, Japan.4 aut
7001 a Spitzer, T. R.4 aut
7001 a MacMillan, M. L.u Univ Minnesota, Med Ctr, Minneapolis, MN USA.4 aut
7001 a Lazaryan, A.u Univ Minnesota, Med Ctr, Div Hematol Oncol, Dept Med, Minneapolis, MN USA.4 aut
7001 a Spellman, S. R.4 aut
7001 a Arora, M.4 aut
7001 a Cutler, C. S.u Dana Farber Canc Inst, Ctr Hematol Oncol, Dept Med Oncol, Boston, MA USA.4 aut
7102 a Massachusetts Gen Hosp, Yawkey 9E 9052 55 Fruit St, Boston, MA 02114 USA.b Med Coll Wisconsin, Ctr Int Blood, Marrow Transplant Res, Dept Med, Milwaukee, WI USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI USA.4 org
7730 t Bone Marrow Transplantationd : NATURE PUBLISHING GROUPg 52:3, s. 400-408q 52:3<400-408x 0268-3369x 1476-5365
8564 u https://www.nature.com/articles/bmt2016265.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-320834
8564 8u https://doi.org/10.1038/bmt.2016.265
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:135472726

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy